Published in Eye (Lond) on October 23, 2015
Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond) (2016) 0.78
Insensitivity of PI3K/Akt/GSK3 signaling in peripheral blood mononuclear cells of age-related macular degeneration patients. J Biomed Res (2017) 0.77
Correlation of neutrophil/lymphocyte and platelet/lymphocyte ratio with visual acuity and macular thickness in age-related macular degeneration. Int J Ophthalmol (2017) 0.76
Can innate and autoimmune reactivity forecast early and advance stages of age-related macular degeneration? Autoimmun Rev (2017) 0.76
Differential Expression of Complement Markers in Normal and AMD Transmitochondrial Cybrids. PLoS One (2016) 0.75
Retinal and Circulating miRNAs in Age-Related Macular Degeneration: An In vivo Animal and Human Study. Front Pharmacol (2017) 0.75
Potential protective function of the sterol regulatory element binding factor 1-fatty acid desaturase 1/2 axis in early-stage age-related macular degeneration. Heliyon (2017) 0.75
Complement Components Showed a Time-Dependent Local Expression Pattern in Constant and Acute White Light-Induced Photoreceptor Damage. Front Mol Neurosci (2017) 0.75
Complement factor H polymorphism in age-related macular degeneration. Science (2005) 31.10
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol (2001) 21.37
The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 19.38
Complement factor H variant increases the risk of age-related macular degeneration. Science (2005) 17.95
Complement factor H polymorphism and age-related macular degeneration. Science (2005) 17.79
Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet (2006) 17.36
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A (2005) 13.44
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
Complement. First of two parts. N Engl J Med (2001) 11.16
An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res (2001) 8.38
Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet (2006) 8.33
Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet (2006) 7.49
Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med (2007) 6.47
Complement. Second of two parts. N Engl J Med (2001) 6.32
A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol (2002) 5.57
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol (2003) 5.22
CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat Genet (2006) 4.51
Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res (2001) 4.38
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet (2013) 4.35
Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet (2007) 4.23
Association between C-reactive protein and age-related macular degeneration. JAMA (2004) 4.16
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA (2013) 3.53
Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina (2006) 3.48
The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res (2009) 3.40
Variation near complement factor I is associated with risk of advanced AMD. Eur J Hum Genet (2008) 3.29
Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A (2006) 3.25
Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study. Lancet (2008) 3.21
Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet (2005) 3.19
Complement and its role in innate and adaptive immune responses. Cell Res (2009) 3.07
CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology (2013) 3.01
CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology (2008) 2.90
Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res (2001) 2.87
No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38. Ophthalmology (2014) 2.86
Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84
Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol (2012) 2.83
Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology (2013) 2.82
The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A (2002) 2.74
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis (2002) 2.53
Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci U S A (2006) 2.45
Epidemiology of age-related maculopathy: a review. Eur J Epidemiol (2003) 2.32
Systemic complement activation in age-related macular degeneration. PLoS One (2008) 2.18
Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet (2006) 2.07
Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Experiment Ophthalmol (2012) 2.03
Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol (2007) 2.00
On the efficiency of targeted clinical trials. Stat Med (2005) 1.99
Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology (2007) 1.96
Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol (2007) 1.94
Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol (2005) 1.89
His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form. J Biol Chem (2006) 1.79
A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur J Immunol (2003) 1.77
Immunopathological aspects of age-related macular degeneration. Semin Immunopathol (2008) 1.63
Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci U S A (2006) 1.63
Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A (2011) 1.60
The effect of genetic variants in SERPING1 on the risk of neovascular age-related macular degeneration. Br J Ophthalmol (2010) 1.56
Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci U S A (2011) 1.56
No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese. Hum Genet (2006) 1.54
Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol (1991) 1.48
Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol (2008) 1.47
Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration. J Transl Med (2011) 1.47
Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A (2011) 1.47
Granulomatous reaction to Bruch's membrane in age-related macular degeneration. Arch Ophthalmol (1994) 1.46
Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. J Biol Chem (2010) 1.36
Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol (1995) 1.35
Oxidized phospholipids in the macula increase with age and in eyes with age-related macular degeneration. Mol Vis (2007) 1.33
CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol (2011) 1.33
Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss. J Med Genet (2008) 1.31
Molecular composition of drusen as related to substructural phenotype. Mol Vis (1999) 1.28
Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci (2011) 1.27
Common variation in the SERPING1 gene is not associated with age-related macular degeneration in two independent groups of subjects. Mol Vis (2009) 1.26
Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol (2011) 1.24
Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and ω-3 fatty acids: the Rotterdam study. Arch Ophthalmol (2011) 1.23
C2 and CFB genes in age-related maculopathy and joint action with CFH and LOC387715 genes. PLoS One (2008) 1.22
Estimation of systemic complement C3 activity in age-related macular degeneration. Arch Ophthalmol (2007) 1.22
Support for the involvement of complement factor I in age-related macular degeneration. Eur J Hum Genet (2010) 1.20
Multilocus analysis of age-related macular degeneration. Eur J Hum Genet (2009) 1.18
The LOC387715 polymorphism and age-related macular degeneration: replication in three case-control samples. Invest Ophthalmol Vis Sci (2007) 1.17
Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis (2010) 1.17
Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem (2009) 1.15
C-reactive protein level and risk of aging macula disorder: The Rotterdam Study. Arch Ophthalmol (2007) 1.15
Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration. Ophthalmology (2007) 1.13
Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent. Am J Clin Nutr (2010) 1.12
Complement gene expression in human brain: comparison between normal and Alzheimer disease cases. Brain Res Mol Brain Res (1992) 1.11
Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD). J Clin Apher (2005) 1.11
Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina (2012) 1.11
Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study. Ophthalmology (2013) 1.11
Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina (2013) 1.10
Complement deposition and microglial activation in the outer retina in light-induced retinopathy: inhibition by a 5-HT1A agonist. Invest Ophthalmol Vis Sci (2011) 1.10
The SERPING1 gene and age-related macular degeneration. Lancet (2009) 1.08
Complement mRNA in the mammalian brain: responses to Alzheimer's disease and experimental brain lesioning. Neurobiol Aging (1993) 1.05
Complement component C3 and risk of age-related macular degeneration. Ophthalmology (2009) 1.05
Scavenger receptors for oxidized lipoprotein in age-related macular degeneration. Invest Ophthalmol Vis Sci (2007) 1.04
Complement component 3 (C3) haplotypes and risk of advanced age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 1.02
Contribution of renal secreted complement C3 to the circulating pool in humans. J Immunol (1999) 1.01
Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology (2012) 1.01
Complement factor H polymorphism p.Tyr402His and cuticular Drusen. Arch Ophthalmol (2007) 0.98
Immunohistochemical localization of complement regulatory proteins in the human retina. Histol Histopathol (2012) 0.96